WHO ADVISORY COMMITTEE ON VARIOLA VIRUS RESEARCH REPORT OF THE TWENTY-SECOND MEETING, GENEVA, 4–5 NOVEMBER 2020



GLOBAL INFECTIOUS HAZARDS PREPAREDNESS

WHO ADVISORY COMMITTEE ON VARIOLA VIRUS RESEARCH REPORT OF THE TWENTY-SECOND MEETING, GENEVA, 4–5 NOVEMBER 2020



WHO Advisory Committee on Variola Virus Research: report of the twenty-second meeting, Geneva, 4-5 November 2020

ISBN 978-92-4-002314-7 (electronic version) ISBN 978-92-4-002315-4 (print version)

© World Health Organization 2021

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. WHO Advisory Committee on Variola Virus Research: report of the twenty-second meeting, Geneva, 4-5 November 2020. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of the twenty-second meeting of the WHO Advisory Committee on Variola Virus Research and does not necessarily represent the decisions or the policies of WHO.

CONTENTS

Executive summary	iv
Meeting proceedings	1
Secretariat report	1
Research on human remains	
Variola virus repository reports	4
Research reports and proposals	5
Antivirals	6
Vaccines	
Diagnostics	
Programme of research	
Recommendations	20
Annexes	22
Annex 1 Agenda	
Annex 2 Participants	
Annex 3 Research proposals	
Annex 4 Abstracts of presentations	

EXECUTIVE SUMMARY

The World Health Organization (WHO) Advisory Committee on Variola Virus Research (ACVVR) held its twenty-second meeting on 4–5 November 2020 by video conference. The recommendations of the Committee are summarized in the report.

Variola virus repositories

The Committee received reports on the variola virus collections held by the authorized repositories at the Federal Budgetary Research Institution - State Research Center of Virology and Biotechnology VECTOR, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being (FBRI SRC VB VECTOR, Rospotrebnadzor), Koltsovo, Novosibirsk Oblast, Russian Federation, and by the Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, the United States of America.

Research update

The Committee received reports on progress of approved research using variola virus. Twenty-six additional variola virus isolates held in the CDC collection had been sequenced. COVID-19 had delayed research during the year under review. The Committee recommended approval of four new proposals presented, two each from CDC and VECTOR, and continuation of previously approved projects.

Antiviral agents

Studies with tecovirimat were ongoing to meet regulatory authority post-marketing requirements. A paediatric formulation and an intravenous formulation were also under development. It was planned to assess tecovirimat in conjunction with vaccination with the approved modified vaccinia Ankara vaccine (MVA) in human volunteers. The safety of brincidofovir had been evaluated in clinical trials, with mild and reversible side effects, and regulatory approval was expected shortly. Study of analogues of ST-357, a possible second-line drug, had begun. VECTOR anticipated that phase 2 and 3 trials of NIOCH-14 would begin in 2021. VECTOR also proposed to test 15 new chemical compounds against variola virus in vitro. Both VECTOR and CDC continued to explore individual, or mixtures of, monoclonal antibodies. CDC's humanized mouse model had displayed sensitivity to variola infection with a disease profile reminiscent of human infection.

Vaccines

Studies of the approved MVA vaccine continued in different contexts, including for the prevention of human monkeypox in the Democratic Republic of the Congo; the vaccine had shown an excellent safety profile and a strong memory response in health workers two years after initial vaccination. Canada had extended indications for the vaccine to include prevention of monkeypox and other orthopoxviruses for persons at risk, making the MVA vaccine the first vaccine approved for a wider range of orthopoxviruses. The neutralizing antibody response of LC16m8, a third-generation vaccine licensed in Japan for prevention of smallpox, continued to be assessed. VECTOR continued development of VAC Δ 6, a 4th generation attenuated vaccinia vaccine, and phase 2 and 3 clinical trials were authorized; licensure in the Russian Federation was anticipated for 2022.

Diagnostics

VECTOR continued to assess an immunochemical test kit for rapid, point-of-care detection of orthopoxviruses; the assay was specific and easy to use and suitable for a field setting. CDC was continuing to improve both nucleic acid-based and protein-based rapid diagnostic tests; detection of variola in a lateral flow protein-based assay had shown promising results. The Committee recommended that both laboratories work towards developing test technology that would not require the use of live virus to validate, and that the advances observed during the COVID-19 pandemic could serve as a basis from which to further develop diagnostic techniques for orthopoxviruses.

Paleogenomics

Continuing previous discussions on the issue of research on human remains, where variola virus DNA may be the subject of investigation or an incidental finding, the Committee reviewed options for guidance, and recommended finalizing a risk assessment framework for handling of such DNA. WHO recommendations on the distribution, handling, and synthesis of variola virus DNA would be updated accordingly.

Conclusion

The Committee expressed support for the continued work on potential antiviral agents against smallpox, voicing concern about the time that may be required to develop monoclonal antibodies, and recommended that work continue on the vaccines and diagnostics in development. Regarding diagnostics, including point-of-care tests, the COVID-19 pandemic had led to the rapid development of technologies that may be applicable for orthopoxviruses, and the Committee urged researchers to propose alternative methods that would not require the use of live variola virus. Proposals presented prior to the meeting were recommended for approval. Other recommendations offered by the Committee are summarized in this report.

WHO ADVISORY COMMITTEE ON VARIOLA VIRUS RESEARCH

预览已结束, 完整报告链接和二维码如下:



https://www.yunbaogao.cn/report/index/report?reportId=5_24284